Clinical trials: Placebo Response
Type 2 Diabetes Mellitus (T2DM)
Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus
This study is a first-in-human randomized, double-blind (Investigator and subject), placebo controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo per dose group) adult male and female…
- Trial name
- NCT01835730
- Testing
- PE0139 Injection
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Herpes Zoster
Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
The purpose of this study was to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who had a previous episode of Herpes Zoster (HZ).
- Trial name
- NCT04091451
- Testing
- Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)
- Where
- 3 sites in Russia
- Volunteers
- 1,430 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Safety and Efficacy of WIN-901X in Asthma
This clinical trial is designed to evaluate the efficacy, dose-response and safety of WIN-901X in Asthma patients.
- Trial name
- NCT01820481
- Testing
- WIN-901X dose level 1, WIN-901X dose level 2, WIN-901X dose level 3
- Where
- South Korea
- Volunteers
- 209 people
- Sponsor
- Whanin Pharmaceutical Company
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)
The primary objective of this study was to perform a variety of immunological assays on blood, serum, nasal wash samples, and cells obtained from healthy adult subjects for the purpose of developing assays for application in the…
- Trial name
- NCT00192231
- Testing
- CAIV-T
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Fatigue, End Stage Renal Disease (ESRD)
Lipid Infusion in Dialysis Patients With Endotoxemia
The purpose of this study is to determine whether a phospholipid emulsion is effective in the treatment of chronic endotoxemia in hemodialysis patients.
- Trial name
- LIPIDOSE (NCT00506454)
- Testing
- Lipidose
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sepsicure
Type 2 Diabetes Mellitus
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
Primary objective: The primary objective of this study is to define the dose response of Glymera as measured as the change from baseline in hemoglobin A1c (HbA1c) following 20 weeks of once-weekly dosing.
- Trial name
- NCT01658501
- Testing
- 50 mg PB1023, 70 mg PB1023, 100 mg PB1023
- Where
- 93 sites in United States
- Volunteers
- 593 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Late Onset Neonatal Sepsis, Necrotizing Enterocolitis
Effects of Oral Probiotic Supplementation on the Clinical Status of Very-low-birth-weight Preterm Neonates.
The purpose of this study was to evaluate the safety of a probiotic foodstuff and its influence on emergence and development of natural intestinal flora and the clinical status of premature very low birth weight neonates.
- Conditions
- Late Onset Neonatal Sepsis, Necrotizing Enterocolitis, Infant, Very Low Birth Weight
- Trial name
- NCT02073214
- Testing
- Probiotic
- Volunteers
- 182 people
- Sponsor
- IBSS Biomed S.A.
Ulcerative Colitis
Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
The study is designed to evaluate the clinical efficacy and safety of tralokinumab as compared to placebo. Investigational product will be administered as subcutaneous injection.
- Trial name
- NCT01482884
- Testing
- tralokinumab
- Where
- 28 sites in Czechia, France and 4 more
- Volunteers
- 147 people
- Sponsor
- AstraZeneca
Influenza
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults
This is a Phase I/II, randomised, multicentre, partially double-blind (group 1, 2, 4 and 5), parallel-group study designed to primarily evaluate the safety, tolerability and immune response in older adults (age 50 to 75 years)…
- Trial name
- NCT03437304
- Testing
- Immunose™ FLU 1%, Immunose™ FLU 2%, 200 μl, Immunose™ FLU 2%, 300 μl
- Where
- 5 sites in Sweden
- Volunteers
- 298 people, healthy volunteers welcome
- Sponsor
- Eurocine Vaccines AB
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-1 (NCT05455684)
- Testing
- Aticaprant
- Where
- 120 sites in United States, Argentina and 11 more
- Volunteers
- 513 people
- Sponsor
- Janssen Research & Development, LLC
Platinum Sensitive Relapsed Ovarian Cancer
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
Olaparib administered as monotherapy in the maintenance setting improves progression free survival compared to placebo in patients whose tumours carry loss of function (deleterious or suspected deleterious) somatic BRCA mutations…
- Trial name
- NCT02392676
- Testing
- OLAPARIB
- Where
- 29 sites in United States, Peru and 3 more
- Sponsor
- AstraZeneca
Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor…
- Trial name
- IZAR-2 (NCT06641089)
- Testing
- Sonelokimab, Risankizumab
- Where
- 143 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- MoonLake Immunotherapeutics AG
Influenza, Human
Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses
A single center trial to evaluate the effect of POLB 001 on inflammatory responses following an intradermal LPS challenge in healthy volunteers.
- Trial name
- NCT05765955
- Testing
- POLB 001
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Poolbeg Pharma plc
Herpes Zoster
A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)
The purpose of this study was to assess the safety and tolerability of gamma-irradiated varicella-zoster virus (VZV) vaccine A (Part 1) and gamma-irradiated VZV vaccine B and C (Part 2) and to determine if they were immunogenic…
- Trial name
- NCT00696709
- Testing
- Comparator: V212
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype…
- Trial name
- NCT01435226
- Testing
- GS-5885, GS-9451, tegobuvir
- Where
- 51 sites in United States, Germany
- Volunteers
- 170 people
- Sponsor
- Gilead Sciences
Crohn Disease
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index…
- Trial name
- NCT00552058
- Testing
- certolizumab pegol (CDP870, CZP)
- Where
- 116 sites in United States, Australia and 18 more
- Volunteers
- 439 people
- Sponsor
- UCB Pharma
Major Depressive Disorder
Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder
The purpose of this study is to determine if Liposom Forte will enhance the response to antidepressant therapy with citalopram in elderly patients suffering from Major Depressive Disorder (MDD).
- Trial name
- NCT04975724
- Testing
- Liposom Forte, Citalopram
- Where
- 12 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Ovarian Cancer
D9319C00001- 1L OC Mono Global RCT
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high…
- Trial name
- MONO-OLA1 (NCT04884360)
- Testing
- Olaparib
- Where
- 89 sites in Chile, China and 8 more
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American…
- Trial name
- FINCH 1 (NCT02889796)
- Testing
- Filgotinib, Adalimumab, MTX
- Where
- 230 sites in United States, Argentina and 28 more
- Volunteers
- 1,759 people
- Sponsor
- Gilead Sciences
Chronic Obstructive Pulmonary Disease
A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.
- Trial name
- NCT01168310
- Testing
- Fluticasone Propionate/Formoterol Fumarate, Formoterol Fumarate
- Where
- 23 sites in United States
- Volunteers
- 468 people
- Sponsor
- Dey